Anzeige
Mehr »
Montag, 06.10.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken beweist seine Stärke - und American Critical Minerals sitzt direkt darauf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 858523 | ISIN: JP3256000005 | Ticker-Symbol: KY4
Stuttgart
06.10.25 | 07:57
13,500 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
KYOWA KIRIN CO LTD Chart 1 Jahr
5-Tage-Chart
KYOWA KIRIN CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
13,70014,00018:33
13,70014,00018:33

Aktuelle News zur KYOWA KIRIN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiKura Oncology, Inc.: Kura Oncology And Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition Of Npm1 And Flt3 Mutations In Patients With Newly Diagnosed Acute Myeloid Leukemia (aml)70- Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML - - FLT3 mutations occur in approximately 30%...
► Artikel lesen
29.09.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)96- KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval - - KOMET-017-NIC trial...
► Artikel lesen
25.09.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology8
16.09.Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis19
11.09.Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress321Princeton, NJ and TOKYO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational T-cell...
► Artikel lesen
09.09.Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug2
KYOWA KIRIN Aktie jetzt für 0€ handeln
09.09.Ekzem-Studie: Amgen und Kyowa Kirin melden positive Ergebnisse für Rocatinlimab10
09.09.Amgen and Kyowa Kirin report positive rocatinlimab results in eczema trial11
09.09.Amgen and Kyowa Kirin report positive rocatinlimab data in atopic dermatitis7
09.09.Amgen And Kyowa Kirin Announce Top-line Results From Rocatinlimab Phase 3 Ascend Long-term Extension Study In Adults With Moderate To Severe Atopic Dermatitis276THOUSAND OAKS, Calif. and TOKYO, Sept. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced preliminary top-line results from the ASCEND...
► Artikel lesen
29.07.Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress258PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational...
► Artikel lesen
01.07.Kura Oncology und Kyowa Kirin schließen Vereinbarung zur Co-Vermarktung von Leukämie-Medikament in den USA25
27.06.Dividendenbekanntmachungen (27.06.2025)16.585 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  AGC INC  JP3112000009  105 JPY  0,6216 EUR  ALERUS FINANCIAL CORPORATION  US01446U1034  0,21 USD  0,1795 EUR  ALICO INC  US0162301040  0...
► Artikel lesen
12.06.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress401- Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML -...
► Artikel lesen
03.06.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting268- CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients - - Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups...
► Artikel lesen
02.06.FDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin's Ziftomenib5
02.06.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML337- New Drug Application based on positive results from the Phase 2 KOMET-001 trial - - FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 - - Potential first...
► Artikel lesen
23.05.Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 20257
22.05.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting236- Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd - - Encore presentation planned at EHA 2025 Congress...
► Artikel lesen
14.05.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress369- Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th - - Updated dataset to be presented in oral presentation at EHA2025 Congress...
► Artikel lesen
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1